OverviewSuggest Edit

BioNanomatrix develops nanoscale imaging and analytic platforms that are designed to analyze DNA and other genome-related peptides and proteins. The Company's technology provides analysis of genomic, epigenomic, and proteomic information with sensitivity at the single molecule level. Its products are used in genetic diagnostics, personalized medicine, and biomedical research applications. 
TypePublic
Founded2002
HQSan Diego, CA, US
Websitebionanogenomics.com
Employee Ratings3.9
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2018)77(+19%)
Job Openings38
Revenue (FY, 2020)$8.5 M(-16%)
Share Price (Nov 2021)$5.1
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at BioNano Genomics

Erik Holmlin

Erik Holmlin

President, Chief Executive Officer & Director
David L. Barker

David L. Barker

Chairman
Mark Oldakowski

Mark Oldakowski

Chief Operating Officer
Christopher J. Twomey

Christopher J. Twomey

Director
Christopher Stewart

Christopher Stewart

Chief Financial Officer
Albert Luderer

Albert Luderer

Director
Show more

BioNano Genomics Office Locations

BioNano Genomics has offices in San Diego and London
San Diego, CA, US (HQ)
9640 Towne Centre Dr #100
London, GB
90 Fetter Ln, Holborn
Show all (3)

BioNano Genomics Financials and Metrics

BioNano Genomics Revenue

Embed Graph
View revenue for all periods
BioNano Genomics's revenue was reported to be $8.5 m in FY, 2020
USD

Revenue (Q1, 2021)

3.2m

Gross profit (Q1, 2021)

1.0m

Gross profit margin (Q1, 2021), %

32.9%

Net income (Q1, 2021)

(9.9m)

EBIT (Q1, 2021)

(11.2m)

Market capitalization (12-Nov-2021)

1.5b

Closing stock price (12-Nov-2021)

5.1

Cash (31-Mar-2021)

362.1m

EV

1.1b
BioNano Genomics's current market capitalization is $1.5 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

6.8m9.5m12.0m10.1m8.5m

Revenue growth, %

40%

Cost of goods sold

3.6m6.0m8.7m6.8m5.7m

Gross profit

3.2m3.5m3.3m3.4m2.8m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

2.8m1.9m2.2m3.3m1.1m940.0k3.2m

Cost of goods sold

3.1m1.1m1.6m2.4m856.0k515.0k2.1m

Gross profit

(239.6k)705.7k619.4k937.9k280.0k425.0k1.0m

Gross profit Margin, %

(8%)38%28%28%25%45%33%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.2m1.0m16.5m17.3m38.4m

Accounts Receivable

1.8m3.4m4.5m6.3m2.8m

Prepaid Expenses

1.8m1.1m919.5k1.2m2.2m

Inventories

1.8m1.7m1.1m3.4m3.3m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

20.7m20.8m15.3m8.2m8.1m17.2m362.1m

Accounts Receivable

4.0m4.1m5.0m6.0m4.1m3.2m2.0m

Prepaid Expenses

1.3m1.7m631.9k1.0m1.1m921.0k3.2m

Inventories

2.6m1.4m3.0m2.6m3.6m3.3m3.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.8m)(23.4m)(18.5m)(29.8m)(41.1m)

Depreciation and Amortization

1.1m1.5m1.3m1.1m1.5m

Inventories

(726.1k)(336.0k)(419.0k)(3.6m)(4.2m)

Accounts Payable

(608.7k)1.5m(954.4k)1.4m(1.8m)
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(12.1m)(7.9m)(15.5m)(21.9m)(10.5m)(18.6m)(9.9m)

Depreciation and Amortization

1.2m269.8k536.8k815.0k296.0k591.0k448.0k

Inventories

(2.1m)(337.3k)(2.0m)(1.9m)(635.0k)(1.0m)(961.0k)

Accounts Payable

60.8k(510.5k)2.3m1.0m477.0k150.0k(1.0m)
USDFY, 2016

Debt/Equity

-3.6 x

Debt/Assets

0.4 x

Financial Leverage

-8 x
Show all financial metrics

BioNano Genomics Acquisitions / Subsidiaries

Company NameDateDeal Size
LineagenAugust 24, 2020
BioNano Genomics (Shanghai) Trading Co.
BioNano Genomics UK

BioNano Genomics Revenue Breakdown

Embed Graph

BioNano Genomics revenue breakdown by geographic segment: 46.5% from Asia Pacific, 13.5% from EMEIA and 40.0% from North America

BioNano Genomics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

BioNano Genomics Online and Social Media Presence

Embed Graph

BioNano Genomics Company Culture

  • Overall Culture

    A+

    95/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

BioNano Genomics News and Updates

Bionano Genomics Announces Peer-Reviewed Publication from Johns Hopkins University Outlining a Stepwise Approach to the Adoption of Optical Genome Mapping for Cancer Analysis

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), provider of optical genome mapping (OGM) solutions on the Saphyr® system and the leading software for genomic data visualization, interpretation and reporting, today announced the publication of a study by Johns Hopkins Un…

Bionano Genomics Announces the Appointment of Stephanie Hoyle as VP Corporate Marketing and Alex Helm as VP Strategic Product Marketing

SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced that two former Illumina executives, Stephanie Hoyle and Alex Helm, have j…

Bionano Genomics Announces Major Updates to Its Solve™ and Access™ Data Solutions Adding Significant New Variant Detection, Analysis and Reporting Capabilities for Optical Genome Mapping on the Saphyr® System

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the release of Bionano Solve™ version 3.7 and Bionano Access™ version 1.7 …

Bionano Genomics to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 4, 2021

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the third quarter ended September 30, 2021 and to highligh…

Bionano Genomics Announces American Society of Human Genetics Presentations Featuring Optical Genome Mapping for Genetic Disease and Cancer Research Applications

SAN DIEGO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), developer of the Saphyr® system that uses optical genome mapping (OGM) for the detection and analysis of structural variants (SVs), today announced the American Society of Human Genetics (ASHG) conference lineup of custome…

Thinking about buying stock in Gaotu Techedu, Camber Energy, Sphere 3D, BioNano Genomics, or Southwest Airlines?

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOTU, CEI, ANY, BNGO, and LUV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

BioNano Genomics Blogs

Bionano Genomics Conference Call

The post Bionano Genomics Conference Call appeared first on Bionano Genomics.

2021 Bionano Second Quarter Financial Results Call

The post 2021 Bionano Second Quarter Financial Results Call appeared first on Bionano Genomics.

Annual Cancer Genomics Consortium (CGC) Meeting, August 1 – 4, 2021

The post Annual Cancer Genomics Consortium (CGC) Meeting, August 1 – 4, 2021 appeared first on Bionano Genomics.

2021 Ladenburg Thalmann Healthcare Conference

The post 2021 Ladenburg Thalmann Healthcare Conference appeared first on Bionano Genomics.

2021 Bionano Annual Shareholders Meeting

The post 2021 Bionano Annual Shareholders Meeting appeared first on Bionano Genomics.

Bionano Genomics to Present at the 2021 Oppenheimer MedTech, Tools & Diagnostic Summit

The post Bionano Genomics to Present at the 2021 Oppenheimer MedTech, Tools & Diagnostic Summit appeared first on Bionano Genomics.
Show more

BioNano Genomics Frequently Asked Questions

  • When was BioNano Genomics founded?

    BioNano Genomics was founded in 2002.

  • Who are BioNano Genomics key executives?

    BioNano Genomics's key executives are Erik Holmlin, David L. Barker and Mark Oldakowski.

  • How many employees does BioNano Genomics have?

    BioNano Genomics has 77 employees.

  • What is BioNano Genomics revenue?

    Latest BioNano Genomics annual revenue is $8.5 m.

  • What is BioNano Genomics revenue per employee?

    Latest BioNano Genomics revenue per employee is $110.4 k.

  • Who are BioNano Genomics competitors?

    Competitors of BioNano Genomics include BaseHealth, Predicine and Mammoth Biosciences.

  • Where is BioNano Genomics headquarters?

    BioNano Genomics headquarters is located at 9640 Towne Centre Dr #100, San Diego.

  • Where are BioNano Genomics offices?

    BioNano Genomics has offices in San Diego and London.

  • How many offices does BioNano Genomics have?

    BioNano Genomics has 3 offices.